A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.
In this report is a biologic defined as proteins, peptides, hormones or antibody鈥檚 drugs production by bio-engineered technology, but does not include a vaccine.
The global Biosimilar market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
China鈥檚 core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.
In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer锛寃ith a share about 50%.
This report is a detailed and comprehensive analysis for global Biosimilar market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Biosimilar market size and forecasts, in consumption value ($ Million), 2019-2030
Global Biosimilar market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Biosimilar market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biosimilar market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao, United Laboratory, 3SBIO, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Biosimilar market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
麻豆原创 segment by Application
Cancer
Immunological Diseases
Diabetes
Others
麻豆原创 segment by players, this report covers
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biosimilar, with revenue, gross margin, and global market share of Biosimilar from 2019 to 2024.
Chapter 3, the Biosimilar competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Biosimilar market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biosimilar.
Chapter 13, to describe Biosimilar research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Biosimilar by Type
1.3.1 Overview: Global Biosimilar 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Biosimilar Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Biosimilar Monoclonal Antibodies
1.3.4 Biosimilar Insulin
1.3.5 Others
1.4 Global Biosimilar 麻豆原创 by Application
1.4.1 Overview: Global Biosimilar 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Cancer
1.4.3 Immunological Diseases
1.4.4 Diabetes
1.4.5 Others
1.5 Global Biosimilar 麻豆原创 Size & Forecast
1.6 Global Biosimilar 麻豆原创 Size and Forecast by Region
1.6.1 Global Biosimilar 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Biosimilar 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Biosimilar 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Biosimilar 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Biosimilar 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Biosimilar 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Biosimilar 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Qilu Pharmaceutical
2.1.1 Qilu Pharmaceutical Details
2.1.2 Qilu Pharmaceutical Major Business
2.1.3 Qilu Pharmaceutical Biosimilar Product and Solutions
2.1.4 Qilu Pharmaceutical Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Qilu Pharmaceutical Recent Developments and Future Plans
2.2 Bio-Thera
2.2.1 Bio-Thera Details
2.2.2 Bio-Thera Major Business
2.2.3 Bio-Thera Biosimilar Product and Solutions
2.2.4 Bio-Thera Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Bio-Thera Recent Developments and Future Plans
2.3 Zhejiang Hisun
2.3.1 Zhejiang Hisun Details
2.3.2 Zhejiang Hisun Major Business
2.3.3 Zhejiang Hisun Biosimilar Product and Solutions
2.3.4 Zhejiang Hisun Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Zhejiang Hisun Recent Developments and Future Plans
2.4 Shanghai Henlius
2.4.1 Shanghai Henlius Details
2.4.2 Shanghai Henlius Major Business
2.4.3 Shanghai Henlius Biosimilar Product and Solutions
2.4.4 Shanghai Henlius Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Shanghai Henlius Recent Developments and Future Plans
2.5 Innovent Biologics
2.5.1 Innovent Biologics Details
2.5.2 Innovent Biologics Major Business
2.5.3 Innovent Biologics Biosimilar Product and Solutions
2.5.4 Innovent Biologics Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Innovent Biologics Recent Developments and Future Plans
2.6 Jiangsu Hengrui
2.6.1 Jiangsu Hengrui Details
2.6.2 Jiangsu Hengrui Major Business
2.6.3 Jiangsu Hengrui Biosimilar Product and Solutions
2.6.4 Jiangsu Hengrui Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Jiangsu Hengrui Recent Developments and Future Plans
2.7 Gan&Lee
2.7.1 Gan&Lee Details
2.7.2 Gan&Lee Major Business
2.7.3 Gan&Lee Biosimilar Product and Solutions
2.7.4 Gan&Lee Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Gan&Lee Recent Developments and Future Plans
2.8 Tonghua Dongbao
2.8.1 Tonghua Dongbao Details
2.8.2 Tonghua Dongbao Major Business
2.8.3 Tonghua Dongbao Biosimilar Product and Solutions
2.8.4 Tonghua Dongbao Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Tonghua Dongbao Recent Developments and Future Plans
2.9 United Laboratory
2.9.1 United Laboratory Details
2.9.2 United Laboratory Major Business
2.9.3 United Laboratory Biosimilar Product and Solutions
2.9.4 United Laboratory Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 United Laboratory Recent Developments and Future Plans
2.10 3SBIO
2.10.1 3SBIO Details
2.10.2 3SBIO Major Business
2.10.3 3SBIO Biosimilar Product and Solutions
2.10.4 3SBIO Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 3SBIO Recent Developments and Future Plans
2.11 Luye Pharma
2.11.1 Luye Pharma Details
2.11.2 Luye Pharma Major Business
2.11.3 Luye Pharma Biosimilar Product and Solutions
2.11.4 Luye Pharma Biosimilar Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Luye Pharma Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Biosimilar Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Biosimilar by Company Revenue
3.2.2 Top 3 Biosimilar Players 麻豆原创 Share in 2023
3.2.3 Top 6 Biosimilar Players 麻豆原创 Share in 2023
3.3 Biosimilar 麻豆原创: Overall Company Footprint Analysis
3.3.1 Biosimilar 麻豆原创: Region Footprint
3.3.2 Biosimilar 麻豆原创: Company Product Type Footprint
3.3.3 Biosimilar 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Biosimilar Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Biosimilar 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Biosimilar Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Biosimilar 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Biosimilar Consumption Value by Type (2019-2030)
6.2 North America Biosimilar 麻豆原创 Size by Application (2019-2030)
6.3 North America Biosimilar 麻豆原创 Size by Country
6.3.1 North America Biosimilar Consumption Value by Country (2019-2030)
6.3.2 United States Biosimilar 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Biosimilar 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Biosimilar 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Biosimilar Consumption Value by Type (2019-2030)
7.2 Europe Biosimilar Consumption Value by Application (2019-2030)
7.3 Europe Biosimilar 麻豆原创 Size by Country
7.3.1 Europe Biosimilar Consumption Value by Country (2019-2030)
7.3.2 Germany Biosimilar 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Biosimilar 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Biosimilar 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Biosimilar 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Biosimilar 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Biosimilar Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Biosimilar 麻豆原创 Size by Region
8.3.1 Asia-Pacific Biosimilar Consumption Value by Region (2019-2030)
8.3.2 China Biosimilar 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Biosimilar 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Biosimilar 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Biosimilar 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Biosimilar 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Biosimilar 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Biosimilar Consumption Value by Type (2019-2030)
9.2 South America Biosimilar Consumption Value by Application (2019-2030)
9.3 South America Biosimilar 麻豆原创 Size by Country
9.3.1 South America Biosimilar Consumption Value by Country (2019-2030)
9.3.2 Brazil Biosimilar 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Biosimilar 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Biosimilar Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Biosimilar 麻豆原创 Size by Country
10.3.1 Middle East & Africa Biosimilar Consumption Value by Country (2019-2030)
10.3.2 Turkey Biosimilar 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Biosimilar 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Biosimilar 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Biosimilar 麻豆原创 Drivers
11.2 Biosimilar 麻豆原创 Restraints
11.3 Biosimilar Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Biosimilar Industry Chain
12.2 Biosimilar Upstream Analysis
12.3 Biosimilar Midstream Analysis
12.4 Biosimilar Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
听
听
*If Applicable.
